Treace Medical Q2 revenue up 6% to $44.5M, net loss widens to $0.34/share, reaffirms FY guidance

TREACE MEDICAL CONCEPTS, INC.

2024-Q2 EPS reported -$0.64 revenue$95,563,000

Revenue $44.5M (+6% YoY); gross margin 80.2% vs 81.7% prior year.
Net loss ($21.2M) or ($0.34)/share vs ($12.3M) or ($0.20)/share in Q2 2023.
Adjusted EBITDA loss ($8.7M) vs ($7.7M) a year ago; cash & equivalents $97.0M.
Full-year 2024 revenue guidance reaffirmed at $201M-$211M (7-13% growth); Adj. EBITDA expected to improve ~50%.
CEO highlights planned entry into minimally invasive metatarsal osteotomy market in Q4 2024 and 65 granted U.S. patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.